On 18 December 2006, orphan designation (EU/3/06/422) was granted by the European Commission to Oasmia Pharmaceutical AB, Sweden, for paclitaxel (micellar) for the treatment of ovarian cancer.
|Disease / condition||
Treatment of ovarian cancer
|Date of decision||
|Orphan decision number||
Review of designation
The Committee for Orphan Medicinal Products reviewed the orphan designation of Apealea at the time of marketing authorisation.
The sponsor formally requested the withdrawal of the orphan designation prior to the Committee’s final opinion. More information is available in the withdrawal assessment_report - orphan maintenance.
Sponsor's contact details
For contact details of patients’ organisations whose activities are targeted at rare diseases, see:
- European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.
- Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe;